partial AUCs for locally acting MR [Design Issues]

posted by Susanh – Iceland, 2020-12-04 15:14 (42 d 13:57 ago) – Posting: # 22114
Views: 405

Dear all,

I’m involved in the development of a MR generic drug that is locally acting in the GI tract. Despite the very helpful new EMA guideline (Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract, CPMP/EWP/239/95 Rev. 1, Corr.1*) I´m struggling with designing the BE studies to support submission in EU.

Most problematic is the justification of the cut-off for the required partial AUCs.

Does anyone have suggestions how to approach this problem?

The modified release guideline (Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms EMA/CHMP/EWP/280/96 Rev1) suggests that the cut-off should be half the dosing interval but I fear that this may not be acceptable.

Thanks in advance,


Complete thread:

 Admin contact
21,303 posts in 4,441 threads, 1,488 registered users;
online 10 (0 registered, 10 guests [including 5 identified bots]).
Forum time: Saturday 05:12 UTC (Europe/Vienna)

If you can’t solve a problem, then there is an easier problem
you can solve: find it.    George Pólya

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz